CardiacSense news

CardiacSense – a digital health company that developed and clinically verified a medical grade watch capable of detecting and remotely monitoring Atrial Fibrillation (A-Fib) and Heart Rate Variability (HRV) announced that it received the CE Mark for marketing & sales of the device in the European Union. The indications certified include “detection of Atrial Fibrillation (A-Fib)” and “monitoring of Heart Rate Var

• The agreement was signed with a distributor for the company’s product, which monitors detects fever, respiratory and chronic diseases as well as heart arrhythmias at a uniquely precise level of an ECG device
• The agreement in India brings CardiacSense’s total backlog to over $60 million. The company is in the process of receiving FDA and CE regulatory approvals for marketing in the US and Europe.

CardiacS

• The Company will enable patients to benefit from Cloud-based medical monitoring, on a monthly fee
• ”Towards the market entry of our medical wristwatch, the Company is launching a cloud-based service platform dedicated for end-users and their physicians, which will enable patient monitoring as part of their daily routine, in hospitals and in clinics, as well as sharing medical indices with their physician in real time, aiming to create compre

• CardiacSense is a leading manufacturer of a range of wearable devices for the continuous monitoring of heart arrhythmias and blood pressure
• HSC signs exclusive Distribution Agreement for Australia & New Zealand for watches & wristbands
• HomeStay to integrate CardiacSense solutions in HSC’s IoT Platform for assistive technology

HomeStay Care Limited (ASX: HSC) (“HSC”, or the &ldquo